Presentation is loading. Please wait.

Presentation is loading. Please wait.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Published byMyron Shaw Modified over 6 years ago

Similar presentations

Presentation on theme: "Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients."— Presentation transcript:

1 Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

2 Table 5 Comparison of outcomes between patients who did and patients who did not have vancomycin-resistant enterococcal (VRE) colonization prior to transplantation. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

3 Table 6 Comparison of outcomes among patients with or without newly acquired vancomycin-resistant enterococcal (VRE) colonization after transplantation. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

4 Table 3 Independent risk factors, determined by binary logistic regression, for vancomycin-resistant enterococcal colonization while awaiting liver transplantation. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

5 Table 2 Risk factors for colonization with vancomycin-resistant enterococci (VRE) among 375 patients awaiting liver transplantation. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

6 Table 1 Demographic and clinical characteristics of 375 liver transplantation candidates enrolled in a study of vancomycin-resistant enterococcal colonization and infection. From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

7 Table 7 Vancomycin-resistant enterococcal (VRE) infections among liver transplant recipients.
From: Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study Clin Infect Dis. 2006;42(2): doi: /498903 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Download ppt "Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients."

Similar presentations

Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.

Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Table 1 Characteristics of the 968 Women in the Study Group

Table 1 Characteristics of the 968 Women in the Study Group
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
From: Rotarix: A Rotavirus Vaccine for the World

From: Rotarix: A Rotavirus Vaccine for the World
Table 4.  Effect of vaccination status on serogroup C serum bactericidal antibody (SBA) titers, IgG levels, and avidity indices (AIs) in acute and convalescent.

Table 4.  Effect of vaccination status on serogroup C serum bactericidal antibody (SBA) titers, IgG levels, and avidity indices (AIs) in acute and convalescent.
Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Similar presentations

Ads by Google